Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Syndax Pharmaceuticals excels in Q4, poised for growth in 2023

Syndax Pharmaceuticals demonstrated strong financial and developmental performance in Q4 2022, with promising advancements in Revumenib and axatilimab.
While facing challenges in FDA considerations and safety data optimization, Syndax is well-positioned to capitalize on opportunities in expanding market reach and strategic partnerships.
The company's clear financial guidance, enrollment progress, and strategic initiatives underscore a positive outlook for future growth and commercial success.

Syndax Pharmaceuticals reports strong financials and advances key drug candidates

Syndax Pharmaceuticals shows strong financial position with a focus on pivotal drug candidates.
Analyst interest in drug efficacy and trial progress highlights market engagement.
Challenges include financial losses, specific patient response data, and trial design considerations.
Opportunities lie in growth potential, market expansion, and strategic partnerships.

Syndax Pharmaceuticals reports Q2 progress with focus on innovative treatments

Syndax Pharmaceuticals' Q2 performance reflects financial stability with a focus on promising trial outcomes.
Strengths lie in innovative drug development, market reach strategies, and a differentiated treatment approach.
Challenges include regulatory hurdles, commercialization decisions, and managing financial resources effectively.
Opportunities arise from upcoming data releases, market penetration plans, and showcasing treatment differentiators.

Syndax Pharmaceuticals reports positive trial data and financial stability

Syndax Pharmaceuticals showcases strong performance in pivotal trials, supported by a solid financial position and a focus on expanding into new indications.
Challenges include enrollment diversity and breakthrough therapy designation, but opportunities lie in market expansion and personalized treatment approaches.
Overall, Syndax is well-positioned to advance its pipeline and deliver innovative therapies for leukemia patients, with a focus on quality data and strategic growth.

Syndax Pharmaceuticals advances key drugs towards potential approvals and commercialization

Syndax Pharmaceuticals made notable progress in 2023, positioning itself for potential drug approvals and commercialization in 2024.
While facing challenges in market competition and regulatory processes, the company's strategic collaborations and pipeline advancements signal a proactive growth trajectory.
With a strong financial position, ongoing clinical trials, and a focus on refining dosing strategies, Syndax is poised to capitalize on market opportunities and drive innovation in oncology.

Syndax Pharmaceuticals reports strong Q1 performance and readies for transformative year ahead

Syndax Pharmaceuticals showcased strong performance, financial stability, and commercial readiness in their Q1 2024 Earnings Call, highlighting a promising outlook for the company's future.
While facing challenges in patient response rates and market adoption, Syndax's robust pipeline, strategic financial planning, and commercial expertise position it well for growth and success.
With opportunities for retreatment strategies, regulatory expedited pathways, and new market engagements, Syndax is poised for a transformative year ahead, leveraging its strengths to drive innovation and market expansion.

Syndax Pharmaceuticals excels in Q3 with FDA approvals and strategic partnerships

Syndax Pharmaceuticals delivered a strong performance in Q3 2024, marked by FDA approvals and strategic partnerships. Their financial position is robust, setting the stage for successful commercialization and future pipeline advancements. While challenges exist in a competitive landscape, the company's innovative pipeline and market opportunities position them for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Syndax Pharmaceuticals Inc (SNDX) Q3 2023 Earnings Call Transcript

–  NDA submission initiated for revumenib in R/R KMT2Ar acute leukemia under RTOR  – –  mNPM1 final efficacy data from the Phase 1 portion of AUGMENT-101 demonstrates a 36% CR/CRh rate  – –  Revumenib and axatilimab U.S. registrational filings on track for year-end 2023 completion and potential 2024 approvals  – –  Axatilimab to be featured in plenary session at 65th ASH Annual Meeting  – –  Revumenib pivotal monotherapy results, combination with venetoclax and post-transplant maintenance data to be highlighted at 65th ASH Annual Meeting  – –  Company to host conference call today at 4:30 p.m. ET  – WALTHAM, Mass.

Syndax Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

– Additional data from pivotal AUGMENT-101 trial in R/R KMT2Ar acute leukemia further highlight revumenib's potential best-in-class profile – – 100% ORR (n=7) and manageable safety profile observed in Phase 1 results of SAVE trial, an all-oral combination regimen of revumenib plus venetoclax-decitabine/cedazuridine in R/R AML – – Patients re-started on treatment with revumenib in post-transplant maintenance exhibit durable MRD negative responses – WALTHAM, Mass. , Nov. 2, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that updated data from multiple trials across its clinical program for revumenib, the Company's highly selective, oral menin inhibitor, will be featured in three poster presentations at the 65th American Society of Hematology (ASH) Annual Meeting being held December 9-12, 2023, in San Diego, California.

Syndax Announces Updated Data Supporting Impressive Clinical Profile of Revumenib in Genetically-Defined Acute Leukemias to Be Presented at the 65th ASH Annual Meeting

–  Results support axatilimab's promising safety and efficacy profile, and reinforce its potential as a first-in-class CSF-1R monoclonal antibody in chronic graft-versus-host disease  – –  Syndax and Incyte intend to file a Biologics License Application (BLA) by year-end 2023 – WALTHAM, Mass. , Nov. 2, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that results from the pivotal AGAVE-201 trial of axatilimab, an anti-CSF-1R antibody, in adult and pediatric patients with chronic graft-versus-host disease (cGVHD), will be featured during the Plenary Scientific Session at the 65th American Society of Hematology (ASH) Annual Meeting being held December 9-12, 2023, in San Diego, California.

Syndax Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting

WALTHAM, Mass. , Oct. 26, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its third quarter 2023 financial results and provide a business update on Thursday, November 2, after the close of the U.S. financial markets.

Syndax to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 2, 2023

– Solidifies first-to-market potential for revumenib – – High unmet need in relapsed or refractory KMT2Ar patients in the U.S. provides a strong foundation for revumenib commercial launch – WALTHAM, Mass. , Oct. 24, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the Company will submit a New Drug Application (NDA) for revumenib in relapsed or refractory (R/R) KMT2Ar acute leukemia, including acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL), under the U.S. Food and Drug Administration (FDA) Real-Time Oncology Review (RTOR) program.

Syndax to Initiate NDA Submission of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Under FDA's Real-Time Oncology Review Program

Syndax Pharmaceuticals, Inc. reported positive results from its phase 1/2 trial using revumenib to treat relapsed/refractory leukemia patients. The trial met its primary endpoint with a complete remission rate of 23%, significantly higher than the current standard of care. It is expected that an NDA of revumenib for AML is expected before end of 2023; it is also being evaluated in other patient populations which could expand its potential.

Syndax: Biotech To Watch With Regulatory Filings Before End Of 2023

Syndax Pharmaceuticals (NASDAQ:SNDX) Inc (Syndax Pharmaceuticals (NASDAQ:SNDX)) stock was on the back foot on Monday, after reporting results from a leukaemia drug trial which met its primary endpoint. "We are thrilled to report positive results for revumenib in KMT2Ar acute leukaemia that demonstrate the utility of its practice-changing clinical profile and highlight revumenib's potential as a first- and best-in-class agent," chief executive Michael Metzger said.

Syndax Pharmaceuticals fall despite positive leukemia

– Trial met its primary endpoint with a CR/CRh rate of 23% at interim analysis of the pooled KMT2Ar AML and ALL cohorts (p-value = 0.0036); an additional 14% of patients proceeded to transplant without achieving CR/CRh – – 65% (32/49) overall response rate in KMT2Ar AML; CR/CRh rate of 24.5% – – 50% (7/14) of transplanted patients have initiated, and 21% (3/14) of transplanted patients could initiate revumenib as post-transplant maintenance highlighting opportunity for long-term therapy –  – 6.4-month median duration of CR/CRh as of the data cutoff with 46% continuing in remission – – Favorable safety and tolerability profile; only 6% discontinued due to treatment related adverse events – – Syndax poised to submit FDA filings for revumenib and axatilimab by the end of 2023 – – Syndax to host a conference call today at 8:00 a.m. ET  – WALTHAM, Mass.

Syndax Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stopped Early for Efficacy Following Protocol-Defined Interim Analysis

AMC Entertainment

SmileDirectClub

Syndax Pharmaceuticals Inc. SNDX, -7.10% rose 19% in premarket trading. The clinical stage biopharmaceutical company said late Friday that it would release topline results from its trial of Revumenib to treat certain forms of leukemia.

SmileDirectClub shares plunge after bankruptcy filing, with Syndax and AMC shares climbing and other active stocks

WALTHAM, Mass. , Sept. 29, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will host a conference call and live webcast to share topline results from the pivotal AUGMENT-101 trial in patients with relapsed/refractory KMT2Ar acute leukemia on Monday, October 2, 2023 at 8:00 a.m.

Syndax to Announce Topline Results from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia and Host an Investor Call on October 2, 2023

Syndax is making strides in the adoption of entinostat, a cancer therapeutic used in combination with immune checkpoint therapies. Syndax reported an increase in operating expenses in Q2 2023, but remains financially stable with cash reserves of $418.3 million. Syndax has two leading candidates in its drug pipeline, revumenib and axatilimab, which show promise in treating acute leukemia and chronic graft-versus-host disease (cGVHD) respectively.

Syndax Pharmaceuticals: Positive Axatilimab Phase 2 Results

WALTHAM, Mass. , Aug. 31, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A.

Syndax Announces Participation at the Citi 18th Annual BioPharma Conference

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Sharon Klahre - Head, IR Michael Metzger - CEO Neil Gallagher - President & Head, R&D Keith Goldan - CFO Peter Ordentlich - CSO Anjali Ganguli - CBO Conference Call Participants Phil Nadeau - TD Cowen Anupam Rama - JPMorgan Ashiq Mubarack - Citi Brad Canino - Stifel Michael Schmidt - Guggenheim Peter Lawson - Barclays William Wood - B. Riley Securities Justin Zelin - BTIG Operator Good day, everyone, and welcome to the Syndax Second Quarter 2023 Earnings Conference Call.

Syndax Pharmaceuticals, Inc. (SNDX) Q2 2023 Earnings Call Transcript

– Announced positive topline results from the pivotal AGAVE-201 trial of axatilimab in cGVHD – – Topline data from the pivotal AUGMENT-101 trial of revumenib in KMT2Ar acute leukemia on track for the third quarter of 2023 – – Two U.S. registrational filings expected by the end of 2023 – – Company to host conference call today at 4:30 p.m. ET – WALTHAM, Mass.

Syndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update

WALTHAM, Mass. , July 25, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its second quarter 2023 financial results and provide a business update on Thursday, August 3, after the close of the U.S. financial markets.

Syndax to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 3, 2023

Incyte

– Trial met its primary endpoint across all cohorts with an overall response rate (ORR) of 74% at a dose of 0.3 mg/kg administered every two weeks – –  Data highlight durable response to treatment. At the 0.3 mg/kg dose, 60% of patients who responded to axatilimab were still responding at one year – –  Results continue to support axatilimab's promising safety and efficacy profile, and reinforce its potential as a first-in-class CSF-1R monoclonal antibody in chronic graft-versus-host disease (GVHD) – – Syndax and Incyte intend to file a Biologics License Application (BLA) by year-end 2023; full dataset to be presented at a future medical meeting – – Syndax to host conference call today at 8:30 a.m.

Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

Syndax Pharmaceuticals offers a unique investment opportunity in precision oncology with a strong financial standing and commitment to research and development. The company's drug pipeline includes revumenib, axatilimab, and entinostat, which show potential in addressing unmet needs in cancer treatment and outperforming competitors. Despite potential risks and challenges, Syndax's innovative approach and promising clinical results position it for continued growth and success in the biopharmaceutical sector.

Syndax Pharmaceuticals: Precision Oncology Leveraging Strong Financials And R&D

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - Chief Executive Officer Neil Gallagher - President and Head of R&D Keith Goldan - Chief Financial Officer Dr. Anjali Ganguli - Chief Business Officer Conference Call Participants Madhu Kumar - Goldman Sachs Eva Privitera - TD Cowen Anupam Rama - JPMorgan Yigal Nochomovitz - Citigroup Peter Lawson - Barclays Kalpit Patel - B. Riley Securities Joel Beatty - Baird Dara Azar - Stifel Justin Zelin - BTIG Operator Good day, everyone, and welcome to the Syndax First Quarter 2023 Earnings Conference Call.

Syndax Pharmaceuticals, Inc. (SNDX) Q1 2023 Earnings Call Transcript

– Topline data from the pivotal AGAVE-201 trial of axatilimab in cGVHD on track for mid-2023 – – Topline data from the pivotal AUGMENT-101 trial of revumenib in KMT2Ar acute leukemia on track for the third quarter of 2023 – – Two U.S. registrational filings expected by the end of 2023 – – Company to host conference call today at 4:30 p.m. ET – WALTHAM, Mass.

Syndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update

WALTHAM, Mass. , May 1, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its first quarter 2023 financial results and provide a business update on Monday, May 8, after the close of the U.S. financial markets.

Syndax to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 8, 2023

- Neil Gallagher, M.D., Ph.D. brings to Syndax over 20 years of experience as a leading  oncology drug developer  - WALTHAM, Mass.

Syndax Pharmaceuticals Announces Appointment of Neil Gallagher, M.D., Ph.D. as President, Head of Research and Development

WALTHAM, Mass. , March 15, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) today announced that data from the Phase 1 portion of the ongoing Phase 1/2 AUGMENT-101 trial of revumenib in patients with nucleophosmin mutant (mNPM1) and KMT2A-rearranged (KMT2Ar) relapsed/refractory (R/R) acute leukemia and an analysis describing MEN1 mutations observed in the study have been published in the journal Nature.

Syndax Pharmaceuticals Announces Two Publications in Nature of Data from the Phase 1 Portion of AUGMENT-101 in Acute Leukemia Patients

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q4 2022 Results Conference Call February 28, 2023 4:30 PM ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - Chief Executive Officer Dr. Briggs Morrison - President and Head, R&D Keith Goldan - Chief Financial Officer Dr. Peter Ordentlich - Chief Scientific Officer Dr. Anjali Ganguli - Chief Business Officer Conference Call Participants Omari Baruti - Goldman Sachs Phil Nadeau - Cowen and Company Priyanka Grover - JPMorgan Ashiq Mubarack - Citi Brad Canino - Stifel Peter Lawson - Barclays Kalpit Patel - B. Riley Securities Bert Hazlett - BTIG Joel Beatty - Baird Operator Good day, everyone, and welcome to the Syndax Fourth Quarter 2022 Conference Call.

Syndax Pharmaceuticals, Inc. (SNDX) Q4 2022 Earnings Call Transcript

Syndax Pharmaceuticals, Inc. has two pivotal trials with data readouts coming up in 2023, with possible regulatory filings. They are loaded with cash after a successful offering.

News for Syndax Pharmaceuticals Stock (SNDX)